D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 81 Citations 36,033 293 World Ranking 9215 National Ranking 299

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Disease
  • Cancer

His primary areas of study are Internal medicine, Rheumatoid arthritis, Arthritis, Surgery and Adverse effect. Pharmacology is closely connected to Placebo in his research, which is encompassed under the umbrella topic of Internal medicine. His Rheumatoid arthritis research is multidisciplinary, relying on both Methotrexate, Clinical trial, Intensive care medicine, Rheumatism and Physical therapy.

The concepts of his Physical therapy study are interwoven with issues in Alternative medicine, Evidence-based medicine, Severity of illness and Janus kinase inhibitor. The various areas that Ronald F van Vollenhoven examines in his Arthritis study include Adalimumab and Pharmacotherapy. His Surgery research incorporates themes from Gastroenterology and Infliximab.

His most cited work include:

  • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update (3425 citations)
  • Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. (2280 citations)
  • The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment (1530 citations)

What are the main themes of his work throughout his whole career to date?

Ronald F van Vollenhoven mainly focuses on Internal medicine, Rheumatoid arthritis, Rheumatology, Surgery and Arthritis. His Internal medicine study incorporates themes from Gastroenterology, Placebo and Immunology. His Rheumatoid arthritis study combines topics from a wide range of disciplines, such as Adverse effect, Physical therapy, Clinical trial and Disease.

His Disease research focuses on subjects like Intensive care medicine, which are linked to Antirheumatic Agents. His biological study spans a wide range of topics, including Rheumatism and Confidence interval. He usually deals with Surgery and limits it to topics linked to Cohort and Cohort study.

He most often published in these fields:

  • Internal medicine (76.07%)
  • Rheumatoid arthritis (51.28%)
  • Rheumatology (27.64%)

What were the highlights of his more recent work (between 2017-2021)?

  • Internal medicine (76.07%)
  • Rheumatoid arthritis (51.28%)
  • Placebo (17.38%)

In recent papers he was focusing on the following fields of study:

His primary areas of investigation include Internal medicine, Rheumatoid arthritis, Placebo, Rheumatology and Clinical trial. His Internal medicine study frequently links to adjacent areas such as Gastroenterology. His Rheumatoid arthritis research includes elements of Randomized controlled trial, Abatacept and Arthritis.

His study in Placebo is interdisciplinary in nature, drawing from both Clinical endpoint, Adverse effect and Ustekinumab. His Rheumatology research is multidisciplinary, incorporating elements of Frailty Index, Disease, Family medicine and Confidence interval. His Clinical trial research integrates issues from Post-hoc analysis, Belimumab, Pediatrics and Intensive care medicine.

Between 2017 and 2021, his most popular works were:

  • 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. (372 citations)
  • Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study (128 citations)
  • Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study (128 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Disease
  • Cancer

Ronald F van Vollenhoven mostly deals with Internal medicine, Rheumatoid arthritis, Lupus erythematosus, Intensive care medicine and Adverse effect. His Lupus nephritis, Systemic lupus erythematosus, Adalimumab, Methotrexate and Rheumatology investigations are all subjects of Internal medicine research. His Rheumatoid arthritis study combines topics in areas such as Therapeutic strategy, Selection and Arthritis.

His work in Lupus erythematosus addresses subjects such as Young adult, which are connected to disciplines such as Cohort study, Lupus vasculitis, Severity of illness and Prospective cohort study. The Intensive care medicine study combines topics in areas such as Standard care and Clinical trial. His work is dedicated to discovering how Adverse effect, Placebo are connected with Ustekinumab, Upper respiratory tract infection and Janus kinase inhibitor and other disciplines.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.

Michelle Petri;Ana Maria Orbai;Graciela S. Alarcõn;Caroline Gordon.
Arthritis & Rheumatism (2012)

3514 Citations

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

Josef S Smolen;Robert Landewé;Ferdinand C Breedveld;Maya Buch;Maya Buch.
Annals of the Rheumatic Diseases (2014)

3425 Citations

The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment

Ferdinand C Breedveld;Michael H Weisman;Arthur F Kavanaugh;Stanley B Cohen.
Arthritis & Rheumatism (2006)

2441 Citations

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

Josef S. Smolen;Robert Landewé;Ferdinand C Breedveld;Maxime Dougados.
Annals of the Rheumatic Diseases (2010)

2195 Citations

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.

Paul Emery;Roy Fleischmann;Anna Filipowicz-Sosnowska;Joy Schechtman.
Arthritis & Rheumatism (2006)

1401 Citations

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Richard Furie;Michelle Petri;Omid Zamani;Ricard Cervera.
Arthritis & Rheumatism (2011)

1212 Citations

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force

Josef S Smolen;Ferdinand C Breedveld;Gerd R Burmester;Vivian Bykerk.
Annals of the Rheumatic Diseases (2016)

1121 Citations

Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis

George K Bertsias;Maria Tektonidou;Zahir Amoura;Martin Aringer.
Annals of the Rheumatic Diseases (2012)

1012 Citations

Tofacitinib or adalimumab versus placebo in rheumatoid arthritis

Ronald F. van Vollenhoven;Roy Fleischmann;Stanley Cohen;Eun Bong Lee.
The New England Journal of Medicine (2012)

813 Citations

Systemic lupus erythematosus.

Arvind Kaul;Caroline Gordon;Mary K Crow;Zahi Touma.
Nature Reviews Disease Primers (2016)

773 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Ronald F. van Vollenhoven

Paul Emery

Paul Emery

University of Leeds

Publications: 241

Yoshiya Tanaka

Yoshiya Tanaka

University of Occupational and Environmental Health Japan

Publications: 202

Josef S. Smolen

Josef S. Smolen

Medical University of Vienna

Publications: 174

Tsutomu Takeuchi

Tsutomu Takeuchi

Keio University

Publications: 141

Désirée van der Heijde

Désirée van der Heijde

Leiden University Medical Center

Publications: 115

Bernard Combe

Bernard Combe

University of Montpellier

Publications: 111

Jeffrey R. Curtis

Jeffrey R. Curtis

University of Alabama at Birmingham

Publications: 110

Michelle Petri

Michelle Petri

Johns Hopkins University School of Medicine

Publications: 106

Xavier Mariette

Xavier Mariette

University of Paris-Sud

Publications: 105

Tore K. Kvien

Tore K. Kvien

University of Oslo

Publications: 104

Maxime Dougados

Maxime Dougados

Hôpital Cochin

Publications: 102

Robert Landewé

Robert Landewé

University of Amsterdam

Publications: 100

Daniel Aletaha

Daniel Aletaha

Medical University of Vienna

Publications: 99

David A. Isenberg

David A. Isenberg

University College London

Publications: 93

Bruno Fautrel

Bruno Fautrel

Université Paris Cité

Publications: 90

Edward C. Keystone

Edward C. Keystone

University of Toronto

Publications: 89

Trending Scientists

Dirk Grunwald

Dirk Grunwald

University of Colorado Boulder

Andrew Nguyen

Andrew Nguyen

Applied Materials (United States)

Christoph Schick

Christoph Schick

University of Rostock

Diego J. Ramón

Diego J. Ramón

University of Alicante

Ligui Li

Ligui Li

South China University of Technology

Meyya Meyyappan

Meyya Meyyappan

Ames Research Center

Jeremy L. Gilbert

Jeremy L. Gilbert

Medical University of South Carolina

Haifan Lin

Haifan Lin

Yale University

Michael Balke

Michael Balke

Ludwig-Maximilians-Universität München

Allen C. Eaves

Allen C. Eaves

Stemcell Technologies

Jacques Maclouf

Jacques Maclouf

Lariboisière Hospital

Leif Bjermer

Leif Bjermer

Lund University

Jeffrey J. Martin

Jeffrey J. Martin

Wayne State University

Bruce A. Reitz

Bruce A. Reitz

Stanford University

Margaret A. Shaffer

Margaret A. Shaffer

University of Oklahoma

Su-Yang Xu

Su-Yang Xu

Harvard University

Something went wrong. Please try again later.